Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Antag Therapeutics ApS
Headquarters: Copenhagen, Denmark
Website: https://antagtherapeutics.com/...
Year Founded: 2017
Status: Private
BioCentury | Jan 31, 2025
Finance
Versant, Orbimed lead $65M launch of GIP-focused start-up Helicore
In BioCentury’s Venture Report: Oncomatryx, Quibin raise cash in Spain; Atalanta draws $97M; Forbion’s BioEconomy Fund
BioCentury | Jan 11, 2025
Management Tracks
Faces in new places ahead of JPM: Rubin joining Guggenheim
Week’s management moves include new venture partners at Frazier and updates from Beigene, Intellia and more
BioCentury | Jan 9, 2025
Management Tracks
Bayer vet Moeller to lead Antag
Plus: CMO changes at Sunbird and Cidara, and updates from Aicuris, Renovaro, Noema and more
BioCentury | Dec 17, 2024
Product Development
Obesity newcos aim for differentiation
New targets start to outnumber incretins among start-ups exploring paths to deeper, higher-quality weight loss
BioCentury | Dec 5, 2024
Finance
Broadening Versant’s obesity portfolio, Antag plots clinical path with €80M
Also in BioCentury’s weekly Venture Report: Formela stepping back from Atlas’ new fund, nine-digit rounds for Nuvig and Maze, and more
BioCentury | May 17, 2018
Finance
Europe’s piece of the pie
Where European life science innovators can take the lead
BioCentury | Oct 6, 2017
Emerging Company Profile
Metabolic contrarian
Why Antag thinks blocking GIP is better than agonizing it in metabolic disease
Items per page:
1 - 9 of 9